Contraversies in hypertension management
Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.
11111 COX-2 FDA Advisory Committee Meeting 2005 Rofecoxib Speaker: Ned S. Braunstein, MD Senior Director, Merck Research Labs.
Obesity and Dyslipidemia AR Esteghamati, MD Associate Professor of Internal Medicine Endocrinology and Metabolism Research Center Tehran University of.
Evidence For A Novel Bone-Kidney Axis Regulating Systemic Phosphate Homeostasis L. Darryl Quarles, M.D. Summerfield Endowed Professor of Nephrology University.
Introduction
AIM-HIGH Trial
Evidence For A Novel Bone-Kidney Axis Regulating Systemic Phosphate Homeostasis
De-risking the development programs of CETP inhibitors after the torcetrapib failure: Endothelial function & blood pressure Prof. John Deanfield University.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
